FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder

/PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a clinical-stage biopharmaceutical company developing...

Related Keywords

Germany ,Canada ,Canadian ,Robert Barrow ,Exchange Commission ,National Institute Of Mental Health ,Company Phase ,Drug Administration ,Nasdaq ,Medicine Mindmed Inc ,Mind Medicine ,Investigational New Drug ,Chief Executive Officer ,Generalized Anxiety Disorder ,National Institute ,Mental Health ,Major Depressive Disorder ,Looking Statements ,Mind Medicine Mindmed Inc ,